Provided by Tiger Trade Technology Pte. Ltd.

Caris Life Sciences, Inc.

28.50
+2.459.40%
Post-market: 28.520.0200+0.07%18:14 EDT
Volume:8.84M
Turnover:246.21M
Market Cap:8.04B
PE:76.61
High:28.68
Open:25.80
Low:25.80
Close:26.05
52wk High:34.54
52wk Low:14.19
Shares:282.15M
Float Shares:116.00M
Volume Ratio:2.79
T/O Rate:7.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3720
EPS(LYR):-3.2200
ROE:20.13%
ROA:8.77%
PB:13.59
PE(LYR):-8.85

Loading ...

U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution Medicines

Reuters
·
Apr 14

Caris Life Sciences Initiated at Buy by Jefferies

Dow Jones
·
Apr 13

Jefferies Initiates Caris Life Sciences at Buy With $28 Price Target

MT Newswires Live
·
Apr 13

Caris Life Sciences initiated with a Buy at Jefferies

TIPRANKS
·
Apr 13

Caris Life Sciences Initiated at Neutral by Piper Sandler

Dow Jones
·
Apr 10

Caris Life Sciences initiated with a Neutral at Piper Sandler

TIPRANKS
·
Apr 10

U.S. RESEARCH ROUNDUP-Chevron, Littelfuse, Parker-Hannifin

Reuters
·
Apr 10

Caris Life Sciences Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Apr 07

Caris Life Sciences Inc - Credit Agreement Includes $400 Mln Term Loan, $300 Mln Delayed Draw, $500 Mln Incremental Facility - SEC Filing

THOMSON REUTERS
·
Apr 03

Caris Life Sciences Inc - Enters New Credit Agreement With Blue Owl Capital and Blackstone - SEC Filing

THOMSON REUTERS
·
Apr 03

Caris Life Sciences signs $400 million term loan with Blue Owl, Blackstone lenders

Reuters
·
Apr 03

BRIEF-Caris Life Sciences Launches Caris Chromoseq For Myeloid Malignancies

Reuters
·
Apr 02

Caris Life Sciences Launches Caris ChromoSeq to Aid in Clinical Genomic Evaluation of Myeloid Malignancies

MT Newswires Live
·
Apr 02

Caris Life Sciences Inc - Launches Caris Chromoseq for Myeloid Malignancies

THOMSON REUTERS
·
Apr 02

Why Is Caris Life Sciences Stock Gaining Wednesday?

Benzinga_recent_news
·
Apr 01

Evercore ISI Sticks to Their Buy Rating for Caris Life Sciences, Inc. (CAI)

TIPRANKS
·
Apr 01

Caris Life Sciences initiated with a Buy at Goldman Sachs

TIPRANKS
·
Apr 01

Caris Life Sciences announces finalized Achieve 1 Study results

TIPRANKS
·
Apr 01

Caris finalizes Achieve 1 study, posts 56.8% Stage I sensitivity for Detect test

Reuters
·
Apr 01

Caris Life Sciences announces six oncology studies for AACR 2026; research focus expands across breast, prostate, lung, and colorectal cancers

Reuters
·
Mar 25